Gilhus N E, Lea T
Department of Neurology, Broegelmann Research Laboratory for Microbiology, University of Bergen, Norway.
J Neurol. 1989 Mar;236(3):149-52. doi: 10.1007/BF00314330.
IgG1, IgG2, IgG3 and IgG4 serum concentrations were determined in 49 phenytoin-treated epileptic patients and in 19 untreated epileptic controls, using subclass-specific monoclonal antibodies in an ELISA technique. The IgG3 and IgG4 concentrations were significantly reduced in patients with IgA deficiency (P less than 0.05, P less than 0.01 respectively). In contrast, IgG4 was elevated in the patients in whom phenytoin did not induce an IgA deficiency (P less than 0.05). IgG1 and IgG2 concentrations did not differ in phenytoin-treated and untreated epileptic patients. IgG1, IgG2, IgG3 and IgG4 did not change after withdrawal of phenytoin. IgG subclass concentrations were not significantly correlated with frequency of respiratory tract infections.
采用酶联免疫吸附测定(ELISA)技术,运用亚类特异性单克隆抗体,测定了49例接受苯妥英治疗的癫痫患者及19例未接受治疗的癫痫对照者的血清IgG1、IgG2、IgG3和IgG4浓度。IgA缺乏患者的IgG3和IgG4浓度显著降低(分别为P<0.05,P<0.01)。相比之下,苯妥英未诱发IgA缺乏的患者中IgG4升高(P<0.05)。接受苯妥英治疗和未接受治疗的癫痫患者的IgG1和IgG2浓度无差异。停用苯妥英后,IgG1、IgG2、IgG3和IgG4无变化。IgG亚类浓度与呼吸道感染频率无显著相关性。